You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 63 No. 2, February 2006 TABLE OF CONTENTS
  Archives
  •  Online Features
  This Month in Archives of Neurology
 This Article
 •PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal

This Month in Archives of Neurology

Arch Neurol. 2006;63:171-172.

Testosterone and Cognition

Lu and colleagues (SEE ARTICLE) evaluated testosterone therapy on cognition, neuropsychiatric symptoms, and quality of life in male patients with mild Alzheimer disease and healthy elderly men. For patients with Alzheimer disease, importantly, the testosterone-treated group had significantly greater improvements in the scores on the caregiver version of the quality-of-life scale.


Apolipoprotein E and Dementia in Parkinson Disease

Huang et al (SEE ARTICLE) report after a meta-analysis that the apolipoprotein E {varepsilon}4 allele is associated with a higher prevalence of dementia associated with Parkinson disease.


Steroid-Responsive Encephalopathy With Autoimmune Thyroiditis

Castillo and colleagues (SEE ARTICLE) characterize the clinical, laboratory, and radiologic findings in patients with steroid-responsive encephalopathy with autoimmune thyroiditis and report that the findings are more varied than previously appreciated. Misdiagnosis at presentation is common. This treatable syndrome should be considered even if the thyroid-stimulating hormone levels and erythrocyte sedimentation rate are normal. Editorial perspective is provided by J. Y. Chong, MD, and Lewis P. Rowland, MD. (SEE ARTICLE)


Levodopa-Induced Dyskinesia in Parkinson Disease

Van Gerpen et al (SEE ARTICLE) report that levodopa dyskinesias can be expected to develop in nearly 60% of patients after 10 years, but these will be severe enough to require medication adjustments in only 43% of patients (Figure).


Figure 02061
Figure. Kaplan-Meier estimate and 95% confidence interval for the probability that a patient with Parkinson disease who is taking levodopa will be free of dyskinesias of any severity.



Trial of Etilevodopa in Parkinson Disease

The Parkinson Study Group (SEE ARTICLE) found that despite the theoretical pharmacokinetic advantage of etilevodopa, there was no improvement in total daily time to "on," number of response failures, or "off" time compared with levodopa.


Nondegenerative and Nonvascular Dementia

Knopman and colleagues (SEE ARTICLE) show that nondegenerative and nonvascular dementia causes in their cohort of patients were more common than expected in patients with younger onset of dementia. None of the patients with dementia reverted to normal with treatment of the putative reversible cause.


Synuclein Abnormalities and Clinical Outcome

Holtzer et al (SEE ARTICLE) found that there is no clear relation between quantitative neuropathologic indices of Lewy body abnormalities and clinical outcome. The variability of clinical features in Alzheimer disease was not related to the presence or degree of Lewy body abnormalities.


Vertebral Artery Compression of the Medulla

Savitz et al (SEE ARTICLE) present the largest collection of patients with medullary vascular compression. Further studies are needed to estimate its frequency, natural course, and preferred management.


White Matter Hyperintensity Volume and Decreased Cognitive Functioning

Au and colleagues (SEE ARTICLE) report in their cohort of patients that nondemented individuals with large white matter hyperintensity, as compared with those with less or no white matter hyperintensity, performed significantly worse in cognitive domains generally associated with the frontal lobe and, to a lesser extent, the medial temporal area.


Brain Changes With Congenital Muscular Dystrophy

Mercuri et al (SEE ARTICLE) show magnetic resonance imaging changes in brain in patients with congenital muscular dystrophy and mutations in the fukutin-related protein (FKRP) gene. The severity of brain involvement broadly reflected the severity of the disruption of the {alpha}-dystroglycan glycosylation. This study further highlights the central role that dystroglycan has in neuronal migration.


G93C Mutation in Superoxide Dismutase 1

Régal and colleagues (SEE ARTICLE) found that the G93C mutation in the superoxide dismutase 1 (SOD1) gene was associated with a purely lower motor neuron phenotype without bulbar involvement and with longer survival compared with other subgroups of amyotrophic lateral sclerosis. Their findings demonstrate the independent prognostic value of the G93C mutation.


Absence of Rapid Eye Movement Sleep Behavior Disorder in a Familial Tauopathy

Boeve et al (SEE ARTICLE) provide convincing evidence against nigral degeneration being the primary cause of a rapid eye movement behavior disorder in a familial form of a tauopathy. The difference in frequencies of a rapid eye movement behavior disorder associated with the synucleinopathies compared with the tauopathies suggests differences in the selective vulnerability of brainstem circuits between the synucleinopathies and tauopathies.


Phenotype With Compound Heterozygous Parkin Gene Mutations

Deng and colleagues (SEE ARTICLE) report on the variable phenotypes in patients with mutations in the parkin (PRKN) gene causing autosomal recessive early-onset Parkinson disease. Their findings support the view that complex gene-environment interactions play a role in the pathogenesis of PRKN early-onset Parkinson disease.


Phenotypes With Sjögren-Larsson Syndrome

Lossos et al (SEE ARTICLE) report significant clinical variability and the nonprogressive neurological course of Sjögren-Larsson syndrome in adult siblings with the same ALDH3A2 genotype.







HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2006 American Medical Association. All Rights Reserved.